- Home
- OTLK vs FGEN Comparison
OTLK vs FGEN Comparison
Compare OTLK & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTLK
- FGEN
- Stock Information
- Founded
- OTLK 2010
- FGEN 1993
- Country
- OTLK United States
- FGEN United States
- Employees
- OTLK N/A
- FGEN N/A
- Industry
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- FGEN Biotechnology: Pharmaceutical Preparations
- Sector
- OTLK Health Care
- FGEN Health Care
- Exchange
- OTLK Nasdaq
- FGEN Nasdaq
- Market Cap
- OTLK 42.8M
- FGEN 45.0M
- IPO Year
- OTLK 2016
- FGEN 2014
- Fundamental
- Price
- OTLK $1.46
- FGEN $11.04
- Analyst Decision
- OTLK Buy
- FGEN Strong Buy
- Analyst Count
- OTLK 5
- FGEN 2
- Target Price
- OTLK $5.25
- FGEN $146.50
- AVG Volume (30 Days)
- OTLK 2.5M
- FGEN 29.6K
- Earning Date
- OTLK 08-14-2025
- FGEN 11-11-2025
- Dividend Yield
- OTLK N/A
- FGEN N/A
- EPS Growth
- OTLK N/A
- FGEN N/A
- EPS
- OTLK N/A
- FGEN N/A
- Revenue
- OTLK $1,505,322.00
- FGEN $7,346,000.00
- Revenue This Year
- OTLK N/A
- FGEN N/A
- Revenue Next Year
- OTLK $313.69
- FGEN N/A
- P/E Ratio
- OTLK N/A
- FGEN N/A
- Revenue Growth
- OTLK N/A
- FGEN N/A
- 52 Week Low
- OTLK $0.79
- FGEN $4.50
- 52 Week High
- OTLK $6.98
- FGEN $21.94
- Technical
- Relative Strength Index (RSI)
- OTLK 62.88
- FGEN 48.48
- Support Level
- OTLK $1.18
- FGEN $10.29
- Resistance Level
- OTLK $1.30
- FGEN $11.24
- Average True Range (ATR)
- OTLK 0.10
- FGEN 0.57
- MACD
- OTLK 0.07
- FGEN -0.17
- Stochastic Oscillator
- OTLK 83.63
- FGEN 38.67
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.